Human Papillomavirus–Associated Cancers — United States, 2008–2012

Laura Viens(Office of Science), Mona Saraiya(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lauri E. Markowitz(Centers for Disease Control and Prevention), S. Jane Henley(Centers for Disease Control and Prevention), Meg Watson(Centers for Disease Control and Prevention), Trevor Thompson(Office of Science), Cheryll C. Thomas(Office of Science), Hilda Razzaghi(National Center for Immunization and Respiratory Diseases)
MMWR Morbidity and Mortality Weekly Report
July 7, 2016
10.15585/mmwr.mm6526a1
Cited by 876

Related Papers

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|2.4k
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Prevalence of HPV Infection Among Females in the United States
|JAMA|2007|1.6k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
|PubMed|2015|1.1k